WO2004032876A3 - Deguelin as a chemopreventive agent for lung cancer - Google Patents

Deguelin as a chemopreventive agent for lung cancer Download PDF

Info

Publication number
WO2004032876A3
WO2004032876A3 PCT/US2003/032263 US0332263W WO2004032876A3 WO 2004032876 A3 WO2004032876 A3 WO 2004032876A3 US 0332263 W US0332263 W US 0332263W WO 2004032876 A3 WO2004032876 A3 WO 2004032876A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
deguelin
lung cancer
present
chemopreventive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/032263
Other languages
French (fr)
Other versions
WO2004032876A9 (en
WO2004032876A2 (en
Inventor
Ho-Young Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to EP03776312A priority Critical patent/EP1565181A2/en
Priority to AU2003284081A priority patent/AU2003284081A1/en
Priority to US10/531,140 priority patent/US20060128792A1/en
Publication of WO2004032876A2 publication Critical patent/WO2004032876A2/en
Publication of WO2004032876A9 publication Critical patent/WO2004032876A9/en
Publication of WO2004032876A3 publication Critical patent/WO2004032876A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides the chemopreventive agent deguelin, a natural product isolated from Mundulea serica (Leguminosae), and derivatives thereof, for use in combination with a second agent for inhibiting growth premalignant and malignant lung cancer cells by causing G2/M arrest and apoptosis. Thus, the present invention provides deguelin-based combination therapies for the treatment and prevention of lung cancer. The second agent of the present invention may, in particular, be an inhibitor of the P13K, MAPK or JNK signaling pathways, or a chemotherapeutic agent, or radiotherapeutic agent.
PCT/US2003/032263 2002-10-11 2003-10-10 Deguelin as a chemopreventive agent for lung cancer Ceased WO2004032876A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03776312A EP1565181A2 (en) 2002-10-11 2003-10-10 Deguelin as a chemopreventive agent for lung cancer
AU2003284081A AU2003284081A1 (en) 2002-10-11 2003-10-10 Deguelin as a chemopreventive agent for lung cancer
US10/531,140 US20060128792A1 (en) 2002-10-11 2003-10-10 Deguelin as a chemopreventive agent for lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41796602P 2002-10-11 2002-10-11
US60/417.966 2002-10-11

Publications (3)

Publication Number Publication Date
WO2004032876A2 WO2004032876A2 (en) 2004-04-22
WO2004032876A9 WO2004032876A9 (en) 2004-07-08
WO2004032876A3 true WO2004032876A3 (en) 2005-03-31

Family

ID=32094126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032263 Ceased WO2004032876A2 (en) 2002-10-11 2003-10-10 Deguelin as a chemopreventive agent for lung cancer

Country Status (4)

Country Link
US (1) US20060128792A1 (en)
EP (1) EP1565181A2 (en)
AU (1) AU2003284081A1 (en)
WO (1) WO2004032876A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102365111B (en) * 2009-03-27 2016-06-22 皇家飞利浦电子股份有限公司 The Normal Tissue Complication probability that mark is adaptive
US9248110B2 (en) * 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
CN101904837B (en) * 2010-07-31 2011-12-07 南京大学 Use of rotenone as non-small cell lung cancer cell sensitizer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045165A1 (en) * 1999-02-01 2000-08-03 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5609878A (en) * 1991-06-05 1997-03-11 Gueyne; Jean Insecticide composition of rotenone microspheres

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045165A1 (en) * 1999-02-01 2000-08-03 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 11, no. 10(2), pages 1181S *
DATABASE BIOSIS [online] March 2000 (2000-03-01), LEE H. ET AL: "Lung cancer chemoprevention induced by deguelin, a novel COX2 inhibitor", XP002984861, Database accession no. PREV200000272809 *
DATABASE BIOSIS [online] October 2002 (2002-10-01), LEE H.: "Implication of Akt inhibition in the mechanism by which the chemopreventive agent deguelin induces apoptosis in an in vitro cell model ofhuman lung carcinogenesis", XP002984860, Database accession no. PREV200300021795 *
DATABASE CAPLUS [online] 13 August 1999 (1999-08-13), SCHALLY A.V. AND NAGY A.: "Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors", XP002984865, accession no. STN Database accession no. 1999:503891 *
DATABASE CAPLUS [online] 19 November 2001 (2001-11-19), EVANS T. L. ET AL: "Lung Cancer", XP002984864, accession no. STN Database accession no. 2001:839156 *
DATABASE CAPLUS [online] 3 March 1990 (1990-03-03), BLASKO G. ET AL: "Carbon-13 NMR spectral assignment and evaluation of the cytotoxic potential of rotenone", XP002984863, accession no. STN Database accession no. 1990:69530 *
DATABASE CAPLUS [online] 30 August 2000 (2000-08-30), STEIN R.C. AND WATERFIELD M.D.: "PI3-kinase inhibition: a target for drug developement?", XP002984866, accession no. STN Database accession no. 2000:604479 *
DATABASE CAPLUS [online] 4 August 2000 (2000-08-04), WEBER E. ET AL, XP002984862, accession no. STN Database accession no. 2000:535357 *
EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 141, no. 1, 1999, pages 1 - 14 *
JOURNAL OF NATURAL PRODUCTS, vol. 52, no. 6, 1989, pages 1363 - 1366 *
MOLECULAR MEDICINE TODAY, vol. 6, no. 9, 2000, pages 347 - 358 *
ONCOLOGIST, vol. 6, no. 5, 2001, pages 407 - 414 *
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, pages 856 *

Also Published As

Publication number Publication date
EP1565181A2 (en) 2005-08-24
US20060128792A1 (en) 2006-06-15
AU2003284081A8 (en) 2004-05-04
WO2004032876A9 (en) 2004-07-08
AU2003284081A1 (en) 2004-05-04
WO2004032876A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
HK1080065A1 (en) Sulfonamides having antiangiogenic and anticancer activity
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2002102981A3 (en) SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
WO2006091395A3 (en) Inhibitors of akt activity
WO2001080870A3 (en) Compositions derived from cranberry and grapefruit and therapeutic uses therefor
NO20085373L (en) P38 inhibitors, their preparation and use
WO2004096135A3 (en) Inhibitors of akt activity
WO2000010507A3 (en) Use of melanin for inhibition of angiogenesis and macular degeneration
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO2006015060A3 (en) Isoindoline compounds and methods of their use
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
DK1423384T3 (en) Pyridine derivatives such as Raf kinase inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2004050837A3 (en) Treatment of dna damage related disorders
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2004032876A3 (en) Deguelin as a chemopreventive agent for lung cancer
WO2004032709A3 (en) Inhibition of src for treatment of reperfusion injury related to revascularization
DE60316128D1 (en) N-sulfonylurea APOPTOSIS PROMOTERS
EP1558282A4 (en) ANTICANCER COMPOSITIONS AND AGAINST INFECTIOUS DISEASES, AND METHODS OF USE THEREOF
WO2005000196A3 (en) Inhibition of egr-1 expression by rpar-ϝ agonista and related compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20

WWE Wipo information: entry into national phase

Ref document number: 2003776312

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003776312

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006128792

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10531140

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10531140

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003776312

Country of ref document: EP